Overview

• Consumer Protection Commission No. 3 imposed a 450 UIT penalty (S/2,407,500), the maximum allowed under Peru’s Consumer Protection and Defense Code.
• The sanction followed findings that controllable failures in Medifarma’s production process led to distribution of a product posing an unjustified risk to health.
• Regulators initiated the case in April 2025 after reports of harmed patients and fatalities in Lima and several regions.
• Ordered remedies require Medifarma to cover necessary medical care for victims, pay funeral expenses where applicable, and implement a compliance program.
• The ruling is administrative and first-instance, and Medifarma may appeal for a second-instance review by Indecopi’s consumer protection chamber.